Kinase Inhibitor Screening in Myeloid Malignancies

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Kinase pathways are primary effectors of many targeted therapy approaches for cancer. Kinase pathways can be dysregulated by mechanisms far more diverse than chromosomal rearrangements or point mutations, which drove the initial application of kinase inhibitors to cancer. Functional screening with kinase inhibitors is one tool by which we can understand the diversity of target kinases and candidate drugs for patients before fully understanding the mechanistic rationale for kinase pathway dysregulation. By combining functional screening with genomic data, it is also possible to accelerate understanding of these mechanistic underpinnings.

Original languageEnglish (US)
Pages (from-to)693-704
Number of pages12
JournalHematology/Oncology Clinics of North America
Volume31
Issue number4
DOIs
StatePublished - Aug 1 2017

Fingerprint

Phosphotransferases
Neoplasms
Point Mutation
Pharmaceutical Preparations
Therapeutics

Keywords

  • Atypical CML
  • Chronic neutrophilic leukemia
  • Functional genomics
  • Functional screening
  • Personalized medicine
  • Precision medicine
  • Small-molecule inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Kinase Inhibitor Screening in Myeloid Malignancies. / Tyner, Jeffrey.

In: Hematology/Oncology Clinics of North America, Vol. 31, No. 4, 01.08.2017, p. 693-704.

Research output: Contribution to journalReview article

@article{d847a7f54e384603920f73c8c3f24cbf,
title = "Kinase Inhibitor Screening in Myeloid Malignancies",
abstract = "Kinase pathways are primary effectors of many targeted therapy approaches for cancer. Kinase pathways can be dysregulated by mechanisms far more diverse than chromosomal rearrangements or point mutations, which drove the initial application of kinase inhibitors to cancer. Functional screening with kinase inhibitors is one tool by which we can understand the diversity of target kinases and candidate drugs for patients before fully understanding the mechanistic rationale for kinase pathway dysregulation. By combining functional screening with genomic data, it is also possible to accelerate understanding of these mechanistic underpinnings.",
keywords = "Atypical CML, Chronic neutrophilic leukemia, Functional genomics, Functional screening, Personalized medicine, Precision medicine, Small-molecule inhibitors",
author = "Jeffrey Tyner",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.hoc.2017.04.004",
language = "English (US)",
volume = "31",
pages = "693--704",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Kinase Inhibitor Screening in Myeloid Malignancies

AU - Tyner, Jeffrey

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Kinase pathways are primary effectors of many targeted therapy approaches for cancer. Kinase pathways can be dysregulated by mechanisms far more diverse than chromosomal rearrangements or point mutations, which drove the initial application of kinase inhibitors to cancer. Functional screening with kinase inhibitors is one tool by which we can understand the diversity of target kinases and candidate drugs for patients before fully understanding the mechanistic rationale for kinase pathway dysregulation. By combining functional screening with genomic data, it is also possible to accelerate understanding of these mechanistic underpinnings.

AB - Kinase pathways are primary effectors of many targeted therapy approaches for cancer. Kinase pathways can be dysregulated by mechanisms far more diverse than chromosomal rearrangements or point mutations, which drove the initial application of kinase inhibitors to cancer. Functional screening with kinase inhibitors is one tool by which we can understand the diversity of target kinases and candidate drugs for patients before fully understanding the mechanistic rationale for kinase pathway dysregulation. By combining functional screening with genomic data, it is also possible to accelerate understanding of these mechanistic underpinnings.

KW - Atypical CML

KW - Chronic neutrophilic leukemia

KW - Functional genomics

KW - Functional screening

KW - Personalized medicine

KW - Precision medicine

KW - Small-molecule inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85019846693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019846693&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2017.04.004

DO - 10.1016/j.hoc.2017.04.004

M3 - Review article

C2 - 28673396

AN - SCOPUS:85019846693

VL - 31

SP - 693

EP - 704

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 4

ER -